ArticleCancer medicine2026
CAPZA1 Suppressed the Progression of Esophageal Squamous Cell Carcinoma by Binding to hnRNP K and PTPB1 to Influence Its mRNA Stability.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeEsophageal squamous cell carcinoma (ESCC) is one of the most aggressive and prevalent cancers in China, a deeper understanding at the molecular level is the cornerstone for advancing precision oncology in ESCC. This study aims to investigate the role of CAPZA1 in ESCC progression. Based on our previous whole genome sequencing (WGS) and whole exome sequencing (WES) data indicating frequent copy number loss of CAPZA1 in ESCC, as well as the presence of a specific single nucleotide polymorphism (SNP, rs373245753 T>G) in its 3'UTR via the dbSNP database (https://www.ncbi.nlm.nih.gov/snp/), we sought to determine the functional and mechanistic impact of CAPZA1 genotypes on ESCC cell behavior. MATERIALS AND
methodsWe identified the SNP rs373245753 within the 3'UTR of the CAPZA1 gene via the dbSNP database. To investigate its functional impact, we established stable ESCC cell lines overexpressing either the CAPZA1[T] or CAPZA1[G] variant and evaluated their migration and invasion capabilities using transwell assays. Subsequently, we performed subcutaneous xenograft experiments by injecting these cells into the lower limbs of mice to monitor tumor growth in vivo. Furthermore, siRNAs were used to efficiently reduce mRNA expression of CAPZA1, then xCELLigence Real-Time Cell Analyzer (RTCA)-MP system and colony formation assay were employed to detect cell proliferation ability. To elucidate the underlying molecular mechanism, we employed biotin-RNA pulldown assays coupled with mass spectrometry, along with RNA immunoprecipitation (RIP) assays, to identify RNA-binding proteins interacting with the CAPZA1 mRNA variants. Finally, we assessed the impact of these proteins on CAPZA1 mRNA stability through mRNA decay assays.
resultsAccording to the dbSNP database, we identified the SNP rs373245753 within the 3'UTR of the CAPZA1 gene. Overexpression of CAPZA1[T] significantly inhibited ESCC cell migration and invasion, while the CAPZA1[G] variant attenuated this suppression both in vivo and in vitro. Biotin-RNA pulldown combined with mass spectrometry and RIP assays showed that CAPZA1[T] mRNA binds to hnRNP K and PTBP1, enhancing its stability and tumor-suppressive function. In contrast, CAPZA1[G] mRNA preferentially bound UPF1, leading to accelerated mRNA decay and loss of tumor suppression.
conclusionCAPZA1 acts as a tumor suppressor in ESCC, with its function dependent on genotype. The CAPZA1[T] variant binds hnRNP K and PTBP1 to stabilize its mRNA and inhibit tumor aggressiveness, whereas the CAPZA1[G] allele promotes UPF1-mediated mRNA decay and diminishes this protective effect. These findings reveal a novel post-transcriptional regulatory mechanism underlying ESCC progression and highlight CAPZA1 genotype as a potential prognostic marker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.